Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 8, 2015, Pages 914-919

  Cui, Shao Bo ^a   Shu, Rong Hua ^a   Yan, Shi Ping ^a   Wu, Hao ^a   Chen, Yong ^a   Wang, Le ^a   Zhu, Qiang ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

anticoagulation therapy; cirrhosis; different doses; enoxaparin; low molecular weight heparin; portal vein thrombosis

Indexed keywords

ENOXAPARIN; IOPROMIDE; FIBRINOLYTIC AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BIOCHEMISTRY; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOPPLER FLOWMETRY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; EPISTAXIS; FEMALE; HEMATURIA; HEPATITIS B; HUMAN; INJECTION SITE BLEEDING; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REAL TIME ULTRASOUND SCANNER; RECANALIZATION; BLEEDING; CHEMICALLY INDUCED; CHINA; COMPARATIVE STUDY; COMPLICATION; DOPPLER ULTRASONOGRAPHY; DRUG ADMINISTRATION; ECHOGRAPHY; MIDDLE AGED; PHLEBOGRAPHY; PORTAL VEIN; PROCEDURES; RADIOGRAPHY; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME; VENOUS THROMBOSIS; VIROLOGY;

ADULT; CHINA; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPATITIS B; HUMANS; INJECTIONS, SUBCUTANEOUS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHLEBOGRAPHY; PORTAL VEIN; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; VENOUS THROMBOSIS;

EID: 84929374888     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000351     Document Type: Article

References (34)

1. Congly SE, Lee SS. Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep 2013; 15:306.
2. Kinjo N, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, Nagao Y, et al. Portal vein thrombosis in liver cirrhosis. World J Hepatol 2014; 6:64-71.
3. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and longterm outcomes. Am J Gastroenterol 2013; 108:568-574.
4. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, et al. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology 2015; 61:660-667.
5. Girleanu I, Stanciu C, Cojocariu C, Boiculese L, Singeap AM, Trifan A. Natural course of nonmalignant partial portal vein thrombosis in cirrhotic patients. Saudi J Gastroenterol 2014; 20:288-292.
6. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012; 32:1465-1476.
7. Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci 2013; 58:1776-1780.
8. Senzolo M, Ferronato C, Burra P, Sartori MT. Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med 2009; 4:161-162.
9. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11:1064-1074.
10. Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, et al. Short-and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011; 60:846-852.
11. Copelan A, Kapoor B, Sands M. Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up. Semin Intervent Radiol 2014; 31:235-242.
12. D'Avola D, Bilbao JI, Zozaya G, Pardo F, Rotellar F, Iñarrairaegui M, et al. Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. Transplant Proc 2012; 44:2603-2605.
13. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012; 57:203-212.
14. Arjal R, Trotter JF. International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis 2009; 13:67-71.
15. Cai M, Zhu K, Huang W, Meng X, He K, Zhou B, et al. Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up. J Vasc Interv Radiol 2013; 24:1808-1816.
16. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44:448-451.
17. Senzolo M, M Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32:919-927.
18. Delgado MG, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10:776-783.
19. Maruyama H, Takahashi M, Shimada T, Yokosuka O. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding. Scand J Gastroenterol 2012; 47:686-691.
20. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54:691-697.
21. DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729-1764.
22. de Franchis R. Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762-768.
23. Berresheim M, Wilkie J, Nerenberg KA, Ibrahim Q, Bungard TJ. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing? Thromb Res 2014; 134:1234-1240.
24. Bechmann LP, Wichert M, Kröger K, Hilgard P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int 2011; 31:1064.
25. Lisman T, Porte RJ. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011; 31:1063.
26. Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31:75-82.
27. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9:1713-1723.
28. Violi F, Ferro D, Basili S. Coagulopathy of chronic liver disease. N Engl J Med 2011; 365:1453-1454.
29. Giannini EG, Savarino V. Which anticoagulant drug should be used to treat portal vein thrombosis in patients with chronic liver disease? Clin Gastroenterol Hepatol 2013; 11:103.
30. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011; 72:581-592.
31. King CS, Holley AB, Moores LK. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. Chest 2013; 143:1106-1116.
32. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143:1253-1260.
33. Deng MH, Liu B, Fang HP, Pan WD, Tang ZF, Deng P, et al. Predictive value of D-dimer for portal vein thrombosis after portal hypertension surgery in hepatitis B virus-related cirrhosis. World J Gastroenterol 2007; 13:6588-6592.
34. Iida H, Aihara T, Ikuta S, Yamanaka N. Predictive factors of portal vein thrombus following splenectomy in patients with severe cirrhosis. Hepatogastroenterology 2014; 61:1552-1555.